Key Highlights
- Owen Murray named CEO of Bend Bioscience, CoreRx, and Societal entities.
- 25+ years of experience in pharmaceutical and healthcare industries.
- Former CEO of Aprecia Pharmaceutical.
- Extensive expertise in global markets and regulatory dynamics.
- Focus on drug product design, formulation development, and commercial manufacturing.
Source: Business Wire
Notable Quotes
- “Mr. Murray’s deep knowledge of pharmaceutical commercialization, gained through his roles in both innovator and service businesses, will enable us to better address our partners’ needs and seize on exciting growth opportunities. His leadership will help us deliver solutions to the unmet needs of patients around the world.” — Robin Smith Hoke, Chairman of the Board at Bend Bioscience, CoreRx, and Societal
- “I am thrilled to join the Company and both lead and unite our established Bend, CoreRx, and Societal businesses. Our goal is to offer exceptional service to the global pharmaceutical industry. The integration of Bend Bioscience’s premier drug product design capabilities with CoreRx’s formulation development, clinical supply, and analytical services, alongside Societal’s robust commercial manufacturing and packaging, creates a powerful combination.” — Owen Murray, CEO at Bend Bioscience, CoreRx, and Societal
SoHC's Take
The appointment of Owen Murray as CEO of the combined Bend Bioscience, CoreRx, and Societal entities marks a strategic move to leverage his extensive industry experience. His proven leadership in both the US and EU markets positions the company to effectively navigate complex regulatory environments and enhance its service offerings. The merger of these three entities under Mr. Murray’s leadership promises to streamline operations and expand their capabilities in drug formulation, development, and manufacturing. This integration is set to provide a robust and reliable supply chain solution, meeting the evolving demands of the global pharmaceutical market.
